Alvotech Appoints Patrik Ling as VP of Investor Relations for Scandinavia

Alvotech has appointed Patrik Ling as VP of Investor Relations Scandinavia. Ling has over 25 years of experience in the life science industry, most recently as Senior Equity Analyst at DNB Carnegie, where he covered life science companies, including Alvotech. He will be based in Stockholm and will focus on expanding Alvotech's shareholder base in Scandinavia.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines, has appointed Patrik Ling as VP of Investor Relations Scandinavia, based in Stockholm. Ling brings over 25 years of experience in the life science industry, most recently serving as Senior Equity Analyst at DNB Carnegie where he covered life science companies, including Alvotech.

The appointment aligns with Alvotech's strategy to expand its Scandinavian shareholder base and strengthen its position as a leading Nordic life science company. Ling's background spans both pharmaceutical and financial sectors, including roles in marketing, sales, portfolio management, and equity analysis.

Patrik Ling, who has more than 25 years of experience in the life-science industry, will be responsible for engaging with Scandinavian investors and helping them better understand Alvotech's strengths and value proposition. "This is a truly exciting time to join Alvotech, with its expanding portfolio of products in the market and in development, supported by a new base of R&D operations in Sweden," said Ling. "Biosimilars play an important role in meeting the growing demand for high-quality biologics and controlling the escalating cost of healthcare."

Róbert Wessman, chairman and CEO of Alvotech, expressed his pleasure in having Ling on board. "It is a great pleasure to have Patrik on board, as he’s been following Alvotech closely over the years and is a highly respected expert within the life science industry in Scandinavia," said Wessman. "Patrik’s background in both pharma and finance, will be a great asset to our team as we continue to broaden our shareholder base in Scandinavia and affirm Alvotech’s role as a leading life science company in the Nordics."

Alvotech's recent financial performance has been robust, with strong growth momentum in the first half of 2025. The company reported product revenues in the first half of the year growing by over 200% and in Q2 2025, product revenues increased by 77% year-on-year [2]. Additionally, Alvotech has been making significant strides in the U.S. market for its Humira biosimilar, with market share gains reaching over 40% in July and expected to reach 50% by year-end [2].

The appointment of Patrik Ling further underscores Alvotech's commitment to strengthening its investor relations and expanding its market presence in Scandinavia. As the company continues to develop and launch new biosimilar products, the addition of Ling's expertise in both the pharmaceutical and financial sectors will be instrumental in driving Alvotech's growth and success.

References:
[1] https://www.stocktitan.net/news/ALVO/alvotech-appoints-patrik-ling-as-vp-of-investor-relations-5rd2v9msjxt8.html
[2] https://seekingalpha.com/news/4485540-alvotech-targets-50-percent-u-s-humira-biosimilar-market-share-by-year-end-as-q2-product